News

Sinensis Life Sciences acquires Spinnovation

Published : Friday, September 19, 2014

Sinensis Life Sciences B.V., Leiden, the Netherlands announced that it has acquired Spinnovation Holding B.V., Oss, the Netherlands, a contract research organisation specialised in the application of nuclear magnetic resonance (NMR) techniques in the pharmaceutical and biotechnological market. Financial terms of the transaction were not disclosed.

Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients

Published : Thursday, September 18, 2014

Galapagos NV announced that more than 100 patients have completed the six month Darwin 1 and 2 studies with GLPG0634 in rheumatoid arthritis and entered Darwin 3, the long term extension study. With the support of their treating physicians, over 90% of the patients who participated in Darwin 1 and Darwin 2 have chosen to participate in Darwin 3, in which all patients will receive long term treatment with Galapagos' highly selective JAK1 inhibitor.

Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy

Published : Wednesday, September 17, 2014

Prosensa Holding N.V., the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that a comprehensive program of re-dosing has commenced, with the first patients now re-dosed in the United States. All dosing in the drisapersen clinical program had been placed on hold by GSK on September 20, 2013, upon announcement of the DEMAND III study results.

Anders Harfstrand joins to-BBB as Chief Executive Officer

Published : Thursday, September 11, 2014

to-BBB, a biopharmaceutical company pioneering treatments for devastating brain diseases, announced the appointment of Dr. Anders Harfstrand as Chief Executive Officer. Dr. Harfstrand brings over 25 years of leadership from both biotech and large pharma to the company.

First investment Innovation Quarter in BabyBloom Healthcare

Published : Wednesday, September 10, 2014

Innovation Quarter announced its first investment in the Leiden company BabyBloom Healthcare.
> Read more in Dutch

1.6 million USD pharma funding for kidney-on-a-chip nephrotoxicity model

Published : Thursday, September 4, 2014

MIMETAS, in a consortium with Radboudumc (Nijmegen) and FHNW (Basel), has received 1.6 million USD funding for development of a kidney-on-a-chip for toxicological applications. A panel of experts from GlaxoSmithKline, Pfizer, Roche, NC3Rs and renowned academic institutions selected MIMETAS’ solution from a strong line-up of competing technologies.

Call for subsidy ‘Praktijkleren’ open until September 15

Published : Thursday, September 4, 2014

The ‘Subsidieregeling praktijkleren’ supports employers in offering apprenticeships to students of universities of applied sciences. 8 Million euro is made available by the Dutch government, to compensate employers for training costs of students.
> Read more in Dutch

Sign up for the Leiden Bio Science Park HR managers meeting on October 2nd!

Published : Wednesday, September 3, 2014

On October 2nd 2014, the Leiden Bio Science Park HR managers meeting will be held. Goal of this meeting is to provide a platform for HR managers at LBSP, to learn and discuss relevant topics and to network.

Apply for support of the Dutch Trade Mission Fund

Published : Wednesday, September 3, 2014

Entrepreneurs can now apply for additional support of the “Oranje Handelsmissiefonds” (abbreviated OHMF) in realizing their international ambitions. From the applicants, ten promising SMEs will be selected and supported with a trade mission package. They  will receive a symbolic cheque of €10,000 for – among other – participation in a fully guided trade mission or international fair.
> Read more in Dutch

Healthy Ageing trade mission Japan & South Korea

Published : Tuesday, September 2, 2014

Between October 27 and November 4 an economic mission will be organized to Japan and South Korea, headed by Minister Henk Kamp. The mission coincides with the state visit of King Willem-Alexander and Queen Máxima to Japan. The trade mission provides an opportunity to companies and research institutions to explore the market, make new contacts or tighten existing contacts.
> Read more in Dutch

Pharming sounded the gong to open Amsterdam market to mark a summer of significant strategic progress for Pharming

Published : Tuesday, September 2, 2014

Sijmen de Vries, CEO of Pharming Group, Jaap Blaak, Chairman of the Board of Supervisory Directors of Pharming Group and the Pharming management team, visited Euronext Amsterdam to sound the gong to signal the opening of the market.

Pharming and Salix announce initiation of clinical study of RUCONEST® for prophylaxis of hereditary angioedema

Published : Thursday, August 28, 2014

Pharming Group NV and Salix Pharmaceuticals, Ltd.  announced the initiation of a clinical study of Ruconest®, (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, for attack prophylaxis in patients with hereditary angioedema (HAE).

Pharming acquires new product leads through the acquisition of certain assets of TRM SASU for € 0.5 Million in cash

Published : Tuesday, August 19, 2014

Biotech company Pharming Group NV announced that through the acquisition of certain assets of Transgenic Rabbit Models SASU (TRM), a private French company in liquidation; for € 0.5 million in cash, it has gained access to five potential new product leads (founder rabbits); recombinant- human (rh)-α-glucosidase for the treatment of Pompe’s disease, rh-α-galactosidase for the treatment of Fabry’s disease, rh-β-cerebrosidase for the treatment of Gaucher’s disease, rh- Factor VIII for the treatment of Haemophilia-A and rh- Factor IX for the treatment of Haemophilia-B.

CF biotech ProQR shoots for a $75M IPO to challenge Vertex

Published : Monday, August 18, 2014

Dutch drug developer ProQR Therapeutics is swinging for a $75 million Wall Street debut to fund its work on a treatment for cystic fibrosis, looking to compete with market leader Vertex Pharmaceuticals ($VRTX). The company, co-founded by former Genzyme CEO Henri Termeer, is preparing a first clinical trial for its lead candidate, QR-010, an RNA-based therapy for CF.

Prosensa and CureDuchenne strengthen long-term collaboration with an additional € 5 million to advance DMD pipeline

Published : Monday, August 11, 2014

Prosensa Holding N.V., the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that an affiliate of CureDuchenne, a US national nonprofit organization dedicated to finding a cure for Duchenne Muscular Dystrophy (DMD), will provide Prosensa with up to €5 million by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. The closing of €4.5 million of the notes is contingent upon specified milestones in the advancement of drisapersen and the Company's other exon skipping candidates in Prosensa's DMD portfolio.

Galapagos receives milestone in osteoarthritis alliance with Servier

Published : Tuesday, August 5, 2014

Galapagos NV announced the achievement of a second partial milestone, thereby completing the nomination of a new pre-clinical candidate in the osteoarthritis alliance with Servier. On March 7, Galapagos announced the receipt of €2M as the first partial milestone. Today's payment remains undisclosed and contributes to Group revenues in the first half of 2014.

Call for ENTENTE- Life Sciences Investment Forum

Published : Monday, July 28, 2014

The FP7 Health project ENTENTE and EuropaBio event will gather 28 European early stage innovative companies active in the health sector and seeking investment opportunities and international exposure. The selected companies will have the opportunity to pitch their innovation, developments and needs to an international jury of about 40 business angels, venture capitalists, corporate investors and other industry experts. The deadline for applications is 29 August.

Interesting mission for (early-stage) medical device and diagnostic companies

Published : Thursday, July 24, 2014

Medical Technology mission Chicago & Boston, 5-10 October 2014. Head of delegation Marc Hendrikse. Full program with partnering sessions, side visits and pitching, linked to AdvaMed conference.
> Read more in Dutch

Dr. Freek Vonk receives prestigious VENI grant from NWO

Published : Wednesday, July 23, 2014

For his research on poisonous snakes Dr. Freek Vonk, researcher at Naturalis Biodiversity Center, received a VENI grant of a quarter million  from the Dutch Organization for Scientific Research (NWO). Freek Vonk will use this amount to clarify the genomes of two species of poisonous snake species.
> Read more Dutch

MorphoSys and Galapagos advance Joint antibody program in Inflammatory diseases into preclinical development

Published : Wednesday, July 23, 2014

MorphoSys AG and Galapagos NV announced that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys' next-generation antibody library Ylanthia and will now be jointly developed in inflammatory diseases.

Volgende »

Newsletter

The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe

RSS

RSS